Pharma Price Cuts: The Impact of Japanese Biennial Price Revisions
Biennial price revisions will result in pharmaceutical price cuts in Japan this month but the world’s second largest pharmaceutical market still holds great opportunity for global pharma, according to latest analysis from Datamonitor Healthcare.
Anantharaman Kavassery Viswanathan, analyst at Datamonitor Healthcare, said: “In this latest round of cuts the market expansion rule will impact 11 active ingredients (APIs) and 22 products which mostly include big-selling DPP-4 inhibitor...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.